Dermata Therapeutics, Inc. [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19
	10-K	10-K	S-1
Operating expenses:
Research and development	3.5	1.6	2.6
General and administrative	4.4	1.6	1.8
Total operating expenses	7.9	3.2	4.5
Loss from operations	-7.9	-3.2	-4.5

Other income and expenses:
Interest income, net	0.0	-0.2	-0.3
Net loss	-7.9	-3.2	-4.7

Net loss per share of common stock, basic and diluted	($2.43)	($1.69)	($2.47)

Weighted-average basic and diluted common shares	4.3	1.9	1.9